High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast Cancer

DNA abnormalities are used in inclusion criteria of clinical trials for treatments with specific targeted molecules. MYC is one of the most powerful oncogenes and is known to be associated with triple-negative breast cancer (TNBC). Its DNA amplification is often part of the targeted DNA-sequencing p...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsuta, Eriko, Yan, Li, Takeshita, Takashi, McDonald, Kerry-Ann, Dasgupta, Subhamoy, Opyrchal, Mateusz, Takabe, Kazuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981812/
https://www.ncbi.nlm.nih.gov/pubmed/31905596
http://dx.doi.org/10.3390/ijms21010217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981812/
https://www.ncbi.nlm.nih.gov/pubmed/31905596
http://dx.doi.org/10.3390/ijms21010217

Ejemplares similares